Edit
Cancer Research Horizons
https://www.cancerresearchhorizons.com/Last activity: 31.03.2026
Active
Cancer Research Horizons is Cancer Research UK's new innovation engine.
We take scientific breakthroughs from the lab bench to the bedside, translating them into effective treatments and diagnostics for cancer patients.
To date, we’ve played an instrumental role in forming over 60 spin-out companies and bringing 11 new cancer drugs to market, borne out of our pioneering research. We are the second biggest licensor of cancer research treatments globally and are part of Cancer Research UK – the world’s largest medical research charity.
With exclusive rights to over £400-million of world-class cancer research we’re a unique and powerful partner in the fight to beat cancer. We work closely with academia and industry to bridge the gap between research and the market, delivering maximum impact for patients. Every penny we make goes back into developing the next breakthroughs, helping bring forward the day when all cancer is conquered.
We take scientific breakthroughs from the lab bench to the bedside, translating them into effective treatments and diagnostics for cancer patients.
To date, we’ve played an instrumental role in forming over 60 spin-out companies and bringing 11 new cancer drugs to market, borne out of our pioneering research. We are the second biggest licensor of cancer research treatments globally and are part of Cancer Research UK – the world’s largest medical research charity.
With exclusive rights to over £400-million of world-class cancer research we’re a unique and powerful partner in the fight to beat cancer. We work closely with academia and industry to bridge the gap between research and the market, delivering maximum impact for patients. Every penny we make goes back into developing the next breakthroughs, helping bring forward the day when all cancer is conquered.
Location: United Kingdom, England, London
Employees: 1001-5000
Founded date: 1902
Mentions in press and media 27
| Date | Title | Description |
| 31.03.2026 | Laigo Bio Secures €17M: SureTACs Platform Targets Cancer, Autoimmune Diseases | Laigo Bio secured €17M seed funding for its SureTACs platform. The biotech pioneers precision membrane protein degradation. Funds will accelerate oncology programs to the clinic. They also advance autoimmune and immunology candidates. The i... |
| 31.03.2026 | Laigo Bio: €17 Million Raised For Biotech Developing SureTACs Precision Protein Degradation Platform | Laigo Bio, a Netherlands-based biotech company developing targeted protein degradation therapies, has completed the final close of its oversubscribed seed financing round, bringing the total raised to €17 million. The latest tranche include... |
| 23.03.2026 | Laigo Bio Closes €17M Seed Funding | Laigo Bio, an Utrecht, The Netherlands-based biotech company, closed the second close of its seed financing round, securing an additional €5.5m, bringing the total raised to €17m. This latest investment comes from new co-lead investor Biova... |
| 24.01.2026 | Infinitopes Secures $35.1M to Advance Precision Cancer Vaccine | Infinitopes, an Oxford-based biotechnology firm, has significantly expanded its seed financing. The company secured an additional $15.4 million. This latest infusion brings total seed funding to $35.1 million. The capital directly targets c... |
| 21.01.2026 | Infinitopes Expands Seed Round To $35.1 Million To Advance Precision Cancer Vaccine Into First-In-Human Trial | Infinitopes has expanded its seed financing to $35.1 million, adding $15.4 million in a second close that the company says will accelerate clinical development of its lead precision cancer vaccine candidate, ITOP1. The financing was co-led ... |
| 21.01.2026 | Infinitopes Raises $15.4M in Seed Extension Funding | Infinitopes, an Oxford, UK-based clinical-stage cancer vaccine biotechnology company, raised additional $15.4M in Seed funding. The round was co-led by Octopus Ventures and new investor Amplify Bio, with participation from new investor Macm... |
| 07.10.2025 | Precision Oncology Pioneer Trogenix Secures Landmark €80M Series A for Curative Cancer Fight | Trogenix, an Edinburgh-based biotech, secured a monumental €80 million Series A funding. This capital empowers its pursuit of curative cancer treatments for aggressive solid tumors. The firm's Odysseus platform uses advanced gene control an... |
| 06.10.2025 | Edinburgh-based BioTech Trogenix lands €80 million to accelerate curative cancer treatments | Trogenix Ltd, a Scottish BioTech company dedicated to innovative cancer therapies, announced the completion of its Series A financing, raising €80 million, to advance its pipeline of potentially curative cancer therapies across multiple agg... |
| 22.08.2025 | Why most AI drug discovery startups struggle — and how Turbine plans to beat the odds | Countless resources and time are expended globally to research and advance novel therapies that end in clinical failure and no patient benefit. Imagine a world where it is possible to predict any potential drug’s effect on translatable biol... |
| 09.05.2025 | The Pulse of Progress: Drug Discovery 2025 in Liverpool | The world of drug discovery is a vibrant tapestry, woven with threads of innovation, collaboration, and hope. This October, Liverpool will host Drug Discovery 2025, a pivotal event that promises to illuminate the path forward in life scienc... |
Show more